显示标签为“recombinant Dpp4”的博文。显示所有博文
显示标签为“recombinant Dpp4”的博文。显示所有博文

2017年2月8日星期三

Scientists have new breakthrough in motor proteins

Researchers at Penn State suggest that motor proteins which pause at the ends of microtubules and produce pushing forces can also stimulate their growth. The function of the proteins is a critical component in understanding cell division and nerve branching and growth, according to research using recombinant horse proteins.

Kinesins are found in multicellular organisms. They are a family of motor proteins. They act as little engines within the cells and transport molecular cargo along microtubules. The microtubules are hollow cylinders of the protein tubulin. They are dynamic and can grow and shrink when the cell change shape.

The researchers are trying to understand more about the motor and what makes the sequences unique since they carry out so many vital functions in the cells.

There are forty-five different kinesin motor proteins in human body in all. The researchers tracked the movements of each one and found that motor pauses at the end of the microtubules. Later it produces pushing forces to slide the microtubules apart and allow the motor to grow the microtubules. Their findings are reported in Nature Communications recently.

They bound microtubules to a microscope slide and added free tubulin subunits together with modified kinesin-5 motor proteins. The results showed that the motor proteins added improve the rate and persistence of microtubule growth.

In conclusion, if we can terminate cancer cell division, new approaches in treatment will come into being. Therefore, understanding more about how kinesin-5 influences microtubule dynamics and its importance in properly segregating genetic material in cell division is of great concern. Flarebio provides you with recombinant proteins of good quality including recombinant Dpp4.

To locate and surveil immune cell of human body with new technology

The immunotherapy of using human immune cells to attack cancer cells is the current international scientific research focus, but how immune cells specifically functions in vivo has always been a mystery. US researchers have recently developed a new method for the first time through recombinant rat proteins to achieve location and surveillance of immune cell of human body.

At this stage, immunotherapy still has its limitations. The effect of immune cells finding and killing cancer cells is sometimes better than conventional cancer therapy, but sometimes does not work. Doctors often have to wait a few months to check whether the tumor shrinks to know whether the immune cells attack cancer cells. If immunotherapy does not work, then the cancer cells may have spread or become more difficult to deal with.

Researchers at Stanford University and other researchers in the United States reported online on the academic journal Science Translational Medicine that they have spent 10 years and have found a way to track immune cells.

They have genetically engineered immune cells from patients and added a "reporter gene", a gene that directs the synthesis of a protein that can be detected by positron emission tomography. After the genetically-modified immune cells being injected back to the human body, by detecting the relevant protein, we can know the location of immune cells, the number of information, and we can analyse whether they are close to the tumor and attack.

The researchers successfully tested this technique in glioblastoma patients. They say that new technologies can also be used to track immune cells against other cancers. "The technique, which can show how the living body's immune system works without removing any human tissue, is unprecedented," says research director, Professor Sanjee Gambier from Stanford University. Flarebio offers superior recombinant proteins such as recombinant Dpp4 at good prices.

2016年11月7日星期一

Researchers release new method of synthesizing antibody drug coupling

Antibody drug conjugates (ADCs) is a class of drugs that have emerged in recent years. By covalently attaching a small molecule to a specific antibody and using recombinant human proteins, people can target the drug to the target region, thereby increasing the effective concentration of the drug in that region while avoiding the potential side effects of systemic administration.

However, ADC application also has its limitations. One of the biggest challenges is how to use a linker that can both stably attach drug molecules to the antibody and can completely release the drug molecules in the target area in certain circumstances in order to exercise its killing effect. In this process, we may encounter two problems: First, the hydrophilicity of drugs or joint molecules may lead to aggregation of ADC, which greatly affects its stability; the second is whether the effective combination of drug molecules and antibodies stand up.

Recently, scientists from Genentech and WuXi PharmaTech have designed a new linker that contains the p-aminophenyl quaternary ammonium salt (PABQ) component, which can be efficiently conjugated with tertiary amine or heterocyclic nitrogen of the drug molecule Antibody, and it can be released in time to play a pharmacological effects, while because the ammonium salt itself overcomes the hydrophobicity of the charge to overcome the problem. The results are published in the recent issue of the journal Nature. The PABQ linker can be released by proteolytic cleavage or disulfide bond cleavage to release drug molecules to suit different vectors or cell environments.

In the case of the release of drug molecules by proteolytic hydrolysis, the investigators chose a commercially available linker molecule as a starter with a maleimide group that reacts with the thiol group on the antibody molecule linked to the antibody; the ValCit dipeptide contains in the target cells can be protease degraded so that the drug molecules can be released. The bianhydroxyl group in the starting molecule becomes an ideal leaving group after reaction with thionyl chloride and covalently linked to it by reaction with a tertiary amine or heterocyclic nitrogen in the drug molecule. This synthesis method needs no protective groups, thus simplifying the steps, and with thionyl chloride generated by the reaction of intermediates to facilitate separation and purification to facilitate the next step with the drug molecules. The generated ADC thus can be degraded by lysosomes in the target cell, thereby releasing the drug intact.

In the case of disulfide bond cleavage using drug molecules, the pyridine thiol group in the linker molecule is replaced with an antibody molecule that also contains a thiol group, forming an ADC molecule assembled by a disulfide bond. When the ADC enters into the cell, it can react with the widespread existence of intracellular reductant glutathione reaction to break the disulfide bonds, which led to cyclization and 1,6-elimination reaction, finally releasing drug molecules.

The researchers found that the ADC prepared by the above method showed a remarkable killing effect on the human lymphoma and intracellular MRSA in mice, thus showing the potential of drug molecules that are difficult to be applied by ADC technology before.

The new connector technology, developed by GeneTek scientist Dr. Thomas H. Pillow, has greatly expanded the scope of ADC applications and provided valuable new insights into targeted therapy for cancer, bacterial or viral infections. Flarebio offers recombinant proteins of good quality such as recombinant Dpp4 at competitive prices.

2016年11月4日星期五

Loneliness may be the early symptom of dementia!

Do you often feel lonely? Be careful, this may be the early symptom of dementia! Researchers at Harvard University conducted a survey through recombinant human proteins on 79 adults, 32% of whom had a high level of Alzheimer's disease and the remainder was normal.

The researchers asked everyone to give their own sense of loneliness grade from a minimum of 3 points up to 12 points, hoping to clarify their cerebral cortex amyloid levels and the relationship between loneliness. Amyloid protein accumulation in the brain will form plaques, causing brain cell death, resulting in memory loss and triggering Alzheimer's disease. The researchers found that volunteers had an average score of 5.3, while those with higher levels of amyloid were more likely to feel lonely and that association was also found in those with high levels of apolipoprotein E.

Dr. Nancy Donovan, who led the study, wrote in the Journal of the American Medical Association Psychiatric Volume that the findings will help doctors identify Alzheimer's disease as early as possible. Statistics show that there are currently 47.5 million dementia patients worldwide, of which the most common one is Alzheimer's disease. It is estimated that the proportion of over the age of 65 elderly people suffering from dementia will reach one-third, and the older they are, the higher the proportion is. Dementia can't be cured and the symptoms can only be relieved through medication. Flarebio offers recombinant proteins of good quality such as recombinant Dpp4.